Cargando…

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia

Development of BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. However, resistance or intolerance to these TKIs still leaves some patients without many treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Price, Kimberly E, Saleem, Najma, Lee, Georgina, Steinberg, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754816/ https://www.ncbi.nlm.nih.gov/pubmed/23986642 http://dx.doi.org/10.2147/OTT.S36980

Ejemplares similares

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou, Theodora, et al.
Publicado: (2017)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Publicado: (2018)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
por: Musumeci, Francesca, et al.
Publicado: (2018)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL
por: Haddad, Fadi, et al.
Publicado: (2023)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
por: Giudice, Valentina, et al.
Publicado: (2020)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

T‐lymphoblastic transformation of chronic myeloid leukemia
por: Al Bakri, Maryam, et al.
Publicado: (2020)

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib
por: Breccia, Massimo, et al.
Publicado: (2016)

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
por: Tusa, Ignazia, et al.
Publicado: (2020)

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
por: Luna, A., et al.
Publicado: (2022)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
por: Garcia Gutierrez, Valentin, et al.
Publicado: (2023)

Chronic myeloid leukemia developing in treated acute promyelocytic leukemia
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2022)

Cytogenetic profile of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in Northern Pakistan
por: Khan, Maria, et al.
Publicado: (2023)

S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS
por: José Cuenca Zamora, Ernesto, et al.
Publicado: (2023)

Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
por: Lee, Jae Wook, et al.
Publicado: (2021)

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Haddad, Fadi, et al.
Publicado: (2023)

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
por: Ribera, Josep-Maria, et al.
Publicado: (2023)

Acute lymphoblastic leukemia to acute myeloid leukemia: an unusual case report of lineage switching
por: Pandit, Sudarshan, et al.
Publicado: (2022)

Myeloid/T-cell acute lymphoblastic leukemia in children and adults
por: Chiaretti, Sabina, et al.
Publicado: (2011)

Blast phase of chronic myeloid leukemia presenting as early T‐cell precursor lymphoblastic leukemia
por: Qiu, Lianqun, et al.
Publicado: (2021)

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
por: Li, Shaoguang
Publicado: (2008)

Acute myeloid leukemia secondary to acute B lymphoblastic leukemia treated with maintenance therapy in a child: A case report
por: Wang, Xiaoning, et al.
Publicado: (2022)

A case of therapy-related acute lymphoblastic leukemia following the treatment of acute myeloid leukemia
por: Shikdar, Sufana, et al.
Publicado: (2022)

Therapy-related acute myeloid leukemia in a patient with B-cell acute lymphoblastic leukemia
por: Gajendra, Smeeta, et al.
Publicado: (2021)

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
por: Caocci, Giovanni, et al.
Publicado: (2019)

Myeloid Sarcoma Presenting with Leukemoid Reaction in a Child Treated for Acute Lymphoblastic Leukemia
por: Canbolat Ayhan, Aylin, et al.
Publicado: (2014)

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
por: Parry, Narissa, et al.
Publicado: (2022)

Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review
por: Kim, Sang-A, et al.
Publicado: (2022)

Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia
por: He, Rui R., et al.
Publicado: (2019)

PB1975: ABL1 GENE DNA SEQUENCING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Kuzmina, Elena, et al.
Publicado: (2023)

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
por: Giglio, Fabio, et al.
Publicado: (2023)

Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study
por: Zhu, Yuanxin, et al.
Publicado: (2023)

CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia
por: GUO, WENJIAN, et al.
Publicado: (2014)

Mixed-phenotypic acute leukemia: cytochemically myeloid and phenotypically early T-cell precursor acute lymphoblastic leukemia
por: Gajendra, Smeeta, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_khr50jagalnna796f2clm5opsv